ReviewJournal of cardiovascular development and disease2022
Pediatric Myocarditis: What Have We Learnt So Far?
Review in Journal of cardiovascular development and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Pooled it
- "Bridging the clinical, molecular and genetic perspectives on myocarditis in post-COVID-19 era".International journal of cardiology. Cardiovascular risk and prevention · 2026Review
- Epidemiology and prognosis of pediatric acute myocarditis: a 5-year retrospective study in Shiraz, South of Iran running title: pediatric acute myocarditis in Iran.BMC cardiovascular disorders · 2025Article
- Cardiac Markers in Pediatric Laboratory Medicine: Critical Review.Diagnostics (Basel, Switzerland) · 2025Review
- How to behave with paediatric myocarditis: imaging methods and clinical considerations.European heart journal. Imaging methods and practice · 2025Review
- Influence of Pyroptosis Induced by NOD-Like Receptor Pyrin Domain-Containing 3 Inflammasomes on Viral Myocarditis in Children.International journal of general medicine · 2025Article
- Diagnostic efficacy of soluble ST2 in pediatric fulminant myocarditis.Frontiers in pediatrics · 2025Article
- Neonatal Enterovirus-Associated Myocarditis in Dizygotic Twins: Myocardial Longitudinal Strain Pattern Analysis.Children (Basel, Switzerland) · 2024Article
- Myocarditis in Athletes: Risk Factors and Relationship with Strenuous Exercise.Sports medicine (Auckland, N.Z.) · 2024Review
- Role of Biomarkers in the Management of Immune-Checkpoint Inhibitor-Related Myocarditis.Current cardiology reports · 2023Review
- Myocarditis in COVID-19: a focus on the pediatric population.American journal of cardiovascular disease · 2023Review
- Non-invasive pediatric cardiac imaging-current status and further perspectives.Molecular and cellular pediatrics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocarditis is an inflammatory disease of the myocardium that is troublesome to diagnose and manage, especially in children. Since the introduction of endomyocardial biopsy (EMB), new diagnostic tools have provided useful data. Especially when enhanced with immunohistochemistry and polymerase chain reaction (PCR) studies, EMB remains the gold standard for the diagnosis. Notably, cardiac magnetic resonance (MRI) is a non-invasive tool that can confirm the diagnosis and has a particular usefulness during the follow-up. The causes of myocarditis are heterogeneous (mostly viral in children). The course and outcome of the illness in the pediatric population represent a complex interaction between etiologic agents and the immune system, which is still not fully understood. The clinical presentation and course of myocarditis vary widely from paucisymptomatic illness to acute heart failure refractory to therapy, arrhythmias, angina-like presentation and sudden cardiac death. In this setting, cardiac biomarkers (i.e., troponins and BNP), although unspecific, can be used to support the diagnosis. Finally, the efficacy of therapeutic strategies is controversial and not confirmed by clinical trials. In this review, we summarized the milestones in diagnosis and provided an overview of the therapeutic options for myocarditis in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.